| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/22/2006 | WO2006065721A2 11, 12-lactone bicyclolides |
| 06/22/2006 | WO2006065711A2 Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists |
| 06/22/2006 | WO2006065710A1 Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
| 06/22/2006 | WO2006065706A1 N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | WO2006065703A1 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 06/22/2006 | WO2006065686A2 Spiro derivatives as lipoxygenase inhibitors |
| 06/22/2006 | WO2006065654A1 Bridged ring nk1 antagonists |
| 06/22/2006 | WO2006065646A1 Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof |
| 06/22/2006 | WO2006065601A2 Inhibitors of akt activity |
| 06/22/2006 | WO2006065600A2 N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | WO2006065590A2 Pyridine and pyrimidine antiviral compositions |
| 06/22/2006 | WO2006065555A2 Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |
| 06/22/2006 | WO2006065480A2 Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| 06/22/2006 | WO2006065479A2 Substituted phenols as active agents inhibiting vegf production |
| 06/22/2006 | WO2006065448A2 Topoisomerase inhibitors and prodrugs |
| 06/22/2006 | WO2006065395A1 Compositions comprising sclareol or derivatives thereof and uses thereof |
| 06/22/2006 | WO2006065392A2 Cancer treatments |
| 06/22/2006 | WO2006065335A2 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
| 06/22/2006 | WO2006065309A1 Use of polyethylene oxide for urogenital infection inhibition |
| 06/22/2006 | WO2006065280A2 Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| 06/22/2006 | WO2006065277A2 Heterocyclic aspartyl protease inhibitors |
| 06/22/2006 | WO2006065233A1 Fused bicycloheterocycle substituted quinuclidine derivatives |
| 06/22/2006 | WO2006065217A1 Nicotinic acetycholine receptor ligands |
| 06/22/2006 | WO2006065216A1 Novel hydantoin derivatives as metalloproteinase inhibitors |
| 06/22/2006 | WO2006065215A1 Novel compounds |
| 06/22/2006 | WO2006065214A1 Tri (hydroxymethyl) methylamine salt or an ethanol amine salt of (2s) -2-ethoxy-3- (4-{2- [hexyl (2- phenylethyl) amino] - 2 -oxoethoxy} phenyl) propanoic acid |
| 06/22/2006 | WO2006065209A1 Nicotinic acetylcholine receptor ligands |
| 06/22/2006 | WO2006065204A1 Substituted aminopyridines and uses thereof |
| 06/22/2006 | WO2006064975A1 Composition and method for accelerating fibulin-5 production and/or enhancing fibulin-5 activity |
| 06/22/2006 | WO2006064957A1 Amide compound and thrombopoietin receptor activator |
| 06/22/2006 | WO2006064945A1 Process for producing muscarine receptor antagonist and intermediate therefor |
| 06/22/2006 | WO2006064944A1 Substituted pyrrole derivative |
| 06/22/2006 | WO2006064914A1 Neuraminidase inhibitor |
| 06/22/2006 | WO2006064889A1 Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
| 06/22/2006 | WO2006064886A1 Agent for regulating bone formation |
| 06/22/2006 | WO2006064826A1 MEDICINAL COMPOSITION CONTAINING FBPase INHIBITOR |
| 06/22/2006 | WO2006064825A1 Therapeutic agent for dry eye |
| 06/22/2006 | WO2006064813A1 Nucleic acid construct and method of transferring mutation into target region by using the same |
| 06/22/2006 | WO2006064780A1 Therapeutic agent for constipation |
| 06/22/2006 | WO2006064779A1 Indolomorphinan derivative having carboxy in 6'-position |
| 06/22/2006 | WO2006064761A1 Adiponectin regultor and foods, drinks, food aditives and drugs containing the same |
| 06/22/2006 | WO2006064757A1 Aminocarboxylic acid derivative and medicinal use thereof |
| 06/22/2006 | WO2006064754A1 Preventive or therapeutic agent for sleep disorder |
| 06/22/2006 | WO2006064744A1 Medicinal composition for treating diabetes |
| 06/22/2006 | WO2006064686A1 Drug and method for preventing or relieving delayed nerve cell death |
| 06/22/2006 | WO2006064576A1 External patches containing etofenamate |
| 06/22/2006 | WO2006064517A2 Methods for the purification of 20(s)-camptothecin |
| 06/22/2006 | WO2006064516A1 Antibiotic combinations for providing total solution to the treatment of infections |
| 06/22/2006 | WO2006064484A1 Azabicyclononene derivatives as renin inhibitors |
| 06/22/2006 | WO2006064449A1 Detoxifying and immunity-booster composition |
| 06/22/2006 | WO2006064375A2 Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases |
| 06/22/2006 | WO2006064355A2 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| 06/22/2006 | WO2006064351A2 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | WO2006064339A1 Chromane derivatives useful as acid pump antagonists |
| 06/22/2006 | WO2006064336A2 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | WO2006064332A1 N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | WO2006064304A1 Acid addition salts of muscarinic receptor antagonists |
| 06/22/2006 | WO2006064298A1 Process for preparation of high-purity meloxicam and meloxicam potassium salt |
| 06/22/2006 | WO2006064291A1 Topical formulations for use in the treatment of prevention of skin cancers |
| 06/22/2006 | WO2006064286A1 Cathepsin s inhibitors |
| 06/22/2006 | WO2006064283A1 Pharmaceutical compounds and compositions |
| 06/22/2006 | WO2006064281A1 A treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 06/22/2006 | WO2006064277A1 Silicon compounds and their use |
| 06/22/2006 | WO2006064263A1 Silicon compounds and their use |
| 06/22/2006 | WO2006064251A1 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 06/22/2006 | WO2006064249A2 Process for the preparation of pantoprazole sodium |
| 06/22/2006 | WO2006064232A1 Amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy) phenoxy)ethyl)phenyl) propanoic acid |
| 06/22/2006 | WO2006064228A2 Thiazolopyramidine compounds for the modulation of chemokine receptor activity |
| 06/22/2006 | WO2006064218A1 Hydantoin derivatives useful as metalloproteinase inhibitors |
| 06/22/2006 | WO2006064217A2 PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF |
| 06/22/2006 | WO2006064196A1 Pyrazolopyrimidine compounds as antitumor agents |
| 06/22/2006 | WO2006064189A1 Oxadiazole derivatives as dgat inhibitors |
| 06/22/2006 | WO2006064075A1 Isoquinoline derivatives as calpain inhibitors |
| 06/22/2006 | WO2006064061A1 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
| 06/22/2006 | WO2006064044A1 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | WO2006064031A1 Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/22/2006 | WO2006064016A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| 06/22/2006 | WO2006064015A2 Diphenylurea derivatives useful as potassium channel activators |
| 06/22/2006 | WO2006063999A1 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| 06/22/2006 | WO2006063863A1 Biaromatic compounds that modulate ppar type receptors, process for preparing them and use thereof in cosmetic or pharmaceutical compositions |
| 06/22/2006 | WO2006063858A1 Pharmaceutical composition containing coated, floating particles |
| 06/22/2006 | WO2006063828A1 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments |
| 06/22/2006 | WO2006063820A1 Pyrazolo-heteroaryl compounds useful to treat tnf-alpha and il-1 mediated diseases |
| 06/22/2006 | WO2006063812A1 3-cycloalkyl-1,2,4-triazin-5(2h)-ones |
| 06/22/2006 | WO2006063811A2 Substituted 1,2,4-triazin-5(2h)-ones |
| 06/22/2006 | WO2006063806A1 Meta-substituted thiazolidinones, the production thereof and their use as medicaments |
| 06/22/2006 | WO2006063805A1 3-amino-pyrazolo[3,4b]pyridines used as inhibitors of protein tyrosine kinases for treating angiogenic, hyperproliferative or neurodegenerative diseases |
| 06/22/2006 | WO2006063801A1 Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl)carbamic acid 2-(s)-hydroxymutilin 14-ester |
| 06/22/2006 | WO2006063791A1 3-benzylthio-1,2,4-triazine-5 (2h)-one as paf-ah inhibitors |
| 06/22/2006 | WO2006063763A1 Pyrrole derivatives having crth2 receptor antagonist activity |
| 06/22/2006 | WO2006063762A1 Dipeptide nitriles |
| 06/22/2006 | WO2006063737A1 Combination therapy comprising telmisartan and hydrochlorothiazide |
| 06/22/2006 | WO2006063732A1 Thieno-pyridine derivatives as gaba-b allosteric enhancers |
| 06/22/2006 | WO2006063722A1 Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them |
| 06/22/2006 | WO2006063718A1 Piperazinyl pyridine derivatives as anti-obesity agents |
| 06/22/2006 | WO2006063715A1 Use of ppar agonists for the treatment of congestive heart failure |
| 06/22/2006 | WO2006063714A1 Pharmaceutical compositions for the treatment of cellulite |
| 06/22/2006 | WO2006063709A1 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease |
| 06/22/2006 | WO2006063708A1 Tetracyclic imidazo-benzodiazepines as gaba receptors modulators |
| 06/22/2006 | WO2006063707A2 Novel pharmaceutical composition containing at least one dolastatin 10 derivative |